drugset
drugset / Trial / NCT04842019

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH

NCT04842019 ↗

Phase 4 Completed 18 enrolled Kyowa Kirin, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in adult Chinese patients with XLH

Timeline

Start
2021-09-28
Primary completion
2023-08-17
Completion
2023-08-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Burosumab Monoclonal antibody 1 mg/kg Subcutaneous

Indications

X-linked hypophosphatemic rickets